SanguiBioTech GmbH conducts research and development related to supplying the human body with oxygen. Patents and expertise, unique technologies and formulations flow into products and their applications. We put the legalization and marketing of these products into the hands of competent specialists: Out-licensing to partners or joint ventures, proceeds from licensing revenues and dividends.

The first major milestone was the market launch of the hemoglobin-based wound spray, Granulox, via the joint venture with SastoMed GmbH. The central major project and strategic focus is the development of artificial oxygen carriers (hemoglobin hyperpolymers) as internal therapy for acute oxygen deficiency. 90% of SanguiBioTech GmbH’s shares are owned by the Sangui BioTech Intl., Inc., which is listed on the OTCQB marketplace and lender and dividend recipient for and from the operational business of SanguiBioTech GmbH.

Granulox – out-licensed to the joint venture company SastoMed GmbH

Based on SanguiBioTech GmbH’s research and development, brought to product maturity and marketing in cooperation with Sander|Strothmann GmbH.

“There were to few new developments, for the most part tried and tested materials were recombined and touted as an innovation. However, according to experts the commendable exception was a new approach to overcoming wound healing inhibiting hypoxia of chronic wounds by means of hemoglobin.”
4th meeting of the “Diabetic Foot Syndrome” (DFS) experts group of the Medical Data Institute (MDI)